References
- Utecht KN Hiles JJ Kolesar J Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors Am J Health Syst Pharm 2006 63 23 2340 2348 17106006
- Dunn CJ Wagstaff AJ Perry CM Plosker GL Goa KL Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation Drugs 2001 61 13 1957 2016 11708766
- International Neoral Renal Transplantation Study Group Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation Am J Transplant 2002 2 2 148 156 12099517
- Mahalati K Belitsky P Sketris I West K Panek R Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation Transplantation 1999 68 1 55 62 10428267
- Canadian Neoral Renal Transplantation Study Group Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation Transplantation 2001 72 6 1024 1032 11579295
- Clase CM Mahalati K Kiberd BA Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling Am J Transplant 2002 2 8 789 795 12243501
- Staatz CE Goodman LK Tett SE Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I Clin Pharmacokinet 2010 49 3 141 175 20170205
- Wu KH Cui YM Guo JF Population pharmacokinetics of cyclosporine in clinical renal transplant patients Drug Metab Dispos 2005 33 9 1268 1275 15932953
- Tokui K Kimata T Uchida K Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients Ther Drug Monit 2004 26 3 287 294 15167630
- Banner NR David OJ Leaver N Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery Transpl Int 2002 15 12 649 654 12478413
- Anglicheau D Thervet E Etienne I CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation Clin Pharmacol Ther 2004 75 5 422 433 15116055
- Hesselink DA van Gelder T van Schaik RH Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes Clin Pharmacol Ther 2004 76 6 545 556 15592326
- Hesselink DA van Schaik RH van der Heiden IP Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 2003 74 3 245 254 12966368
- Yates CR Zhang W Song P The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients J Clin Pharmacol 2003 43 6 555 564 12817518
- Haufroid V Mourad M Van Kerckhove V The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 2004 14 3 147 154 15167702
- Azarpira N Aghdaie MH Behzad-Behbahanie A Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation Exp Clin Transplant 2006 4 1 416 419 16827636
- Hu YF Qiu W Liu ZQ Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation Clin Exp Pharmacol Physiol 2006 33 11 1093 1098 17042920
- Foote CJ Greer W Kiberd BA MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients Transplant Proc 2006 38 9 2847 2849 17112845
- Nolin TD Altered nonrenal drug clearance in ESRD Curr Opin Nephrol Hypertens 2008 17 6 555 559 18941346
- Bechstein WO Neurotoxicity of calcineurin inhibitors: impact and clinical management Transpl Int 2000 13 5 313 326 11052266